A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The present study aims to compare efficacy, side-effects, and treatment adherence of three
different treatment regimens given to antiretroviral naïve HIV-1 infected patients. Treatment
will be initiated in accordance with the Swedish National Guidelines. In the twice daily
(BID) arm (1), which could be considered as a standard regimen at present,
lopinavir/ritonavir, is co-administrated with 2 nucleoside reverse transcriptase inhibitors
(NRTIs) administrated BID. The first once daily (QD) arm (2) combines the protease inhibitor
(PI) atazanavir/ritonavir with 2 NRTIs administrated QD, and in the second QD arm (3), the
non nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz is combined with 2 NRTIs
administrated QD. All drugs used in the study are licensed in the participating countries and
patients will be followed as in clinical practice. Patients could optionally, after informed
consent, be followed with additional measurements of HIV-1 RNA after 1, 2, and 3 weeks of
treatment to asses the kinetics of viral decline after initiation of treatment.